Project Grant R01MH133600

Award Date 11/15/24
Completion Date 10/31/29
Dollars Obligated $440K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68178, USA
Similar Awards
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $237,750 to the University of California, Merced to elucidate the role of the BAF chromatin remodeling complex in experience-induced neuronal gene transcription and synapse maturation, with implications for autism spectrum disorders. The 2-year project aims to determine if the neuronal BAF complex mediates RNA polymerase II elongation...
This Project Grant award from the National Institute of Mental Health (NIMH), under CFDA Program 93.242 - Mental Health Research Grants, will fund a research study at the University of Alabama at Birmingham (UAB) to characterize a genetic mouse model and delineate its function in the brain. The $742,484 award, with a period of performance from January 13, 2025 to October 31, 2029, will support comprehensive experiments to identify novel downstream targets, elucidate behavioral outcome...
The National Institute of Mental Health (NIMH) awarded a $911,929 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Scripps Research Institute in La Jolla, CA on September 5, 2024. The grant will fund a research project titled "Scalable Functional Analysis of Neuropsychiatric Risk Genes with Spatially Integrated In Vivo Perturb-Seq." The project aims to combine high-content in vivo genetic screening with whole brain cytoarchitecture spatial information to bridge the...
This Project Grant award from the National Institute of Mental Health (NIMH), under CFDA Program 93.242 "Mental Health Research Grants", is providing $475,388 to The Broad Institute, Inc. to conduct research characterizing the transcriptional and neuro-immune consequences of loss of the high-confidence bipolar disorder risk gene KDM5B. The project aims to investigate the impact of stress on behavior and gene transcription in wild-type and KDM5B heterozygous mice, as well as...
This federal Project Grant award, with ID K99MH138830, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $120,015.00 award will fund a research project titled "Identifying Transcriptomic Axes Governing Neural Dynamics, Behavior, and States" from January 6, 2025 to December 31, 2026. The project aims to develop a novel technological pipeline that combines large-scale neural activity monitoring in freely...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to investigate the developmental origins of mental illness by studying the structure and function of the human hypothalamus. The $392,500 award to the University of California, Irvine will fund a 5-year research project that will: 1) develop normative brain imaging measures of hypothalamic development from birth to adulthood, 2) assess the impact of...
This $147,656 federal Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to define how novel post-translational modifications (PTMs) on histones are regulated by neuronal activity and to test their role in learning and memory. The key objectives are to: Use primary neuronal culture systems to study how neuronal activation affects histone crotonylation over time, mapping broad dynamic changes and quantifying...
The National Institute of Mental Health (NIMH) awarded a $367,708 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the University of Southern California (USC). The grant, awarded on September 3, 2024, supports a 5-year research project titled "Neural Substrates of Autism and ADHD: Reward Circuitry Connectivity and Individual Differences". The project aims to use cutting-edge neuroimaging and machine learning methods to investigate how the functional...
This Project Grant award from the National Institute of Mental Health (NIMH), under the CFDA 93.242 Mental Health Research Grants program, provides $183,663 in funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the genetic architecture of neuropsychiatric disorders (NPDs) including autism spectrum disorder (ASD), epilepsy, and schizophrenia. The key objectives of this 4-year research project are to: 1) Apply a rare...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $396,250 to Vanderbilt University to conduct research on the regulation of metabotropic glutamate receptor activity by protein/protein interactions. The 5-year project, starting on December 1, 2024, aims to: Test a suite of control agonists, positive allosteric modulators (PAMs), and negative allosteric modulators (NAMs) for activity at mGlu7...

This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $439,804 to Creighton University to conduct research on the epigenetic regulation of the neuroendocrine axis in brain development and behavior.

The key objectives of this 5-year research project are to: 1) specify the role of the lysine methyltransferase 5B (KMT5B) gene in the paracrine (local brain) production of insulin-like growth factors (IGFs), 2) define how endocrine (circulating) expression of IGFs changes over time relative to KMT5B expression and impacts brain expression and behavioral phenotypes, and 3) identify the cell types where KMT5B regulates IGF expression and whether these effects can be therapeutically rescued. The research aims to increase understanding of how KMT5B interacts with the neuroendocrine axis, how IGFs are epigenetically regulated, and how IGF1 and IGF2 are regulated in different tissues over time, with the goal of defining the contribution of KMT5B to autism clinical features and illuminating novel drug targets for treatment.

Generated 7/15/25, 2:45 AM